A therapeutic strategy that would mitigate the events leading to hyperplasia and facilitate re-endothelialization of an injured artery after balloon angioplasty could be effective for a long-term patency of the artery. It is hypothesized that erythropoietin (EPO), which has both anti-inflammatory and antiapoptotic properties, will prevent hyperplasia, and its ability to proliferate and mobilize endothelial progenitor cells will re-endothelialize the injured artery. To test this hypothesis, EPO (5000 IU/kg) in solution was injected intraperitoneally 6 hours before vascular injury and then on every alternate day for a week or as a single dose (5000 IU/kg) in a sustained release gel formulation 1 week before the vascular injury. Morphometric analysis revealed nearly continuous re-endothelialization of the injured artery in EPO solution-treated animals (90% vs less than 20% in saline control); however, the treatment also caused excessive neointima formation (intima/media ratio, 2.10 ± 0.09 vs 1.60 ± 0.02 saline control, n = 5, P
CITATION STYLE
Reddy, M. K., Vasir, J. K., Hegde, G. V., Joshi, S. S., & Labhasetwar, V. (2007). Erythropoietin induces excessive neointima formation: A study in a rat carotid artery model of vascular injury. Journal of Cardiovascular Pharmacology and Therapeutics, 12(3), 237–247. https://doi.org/10.1177/1074248406297326
Mendeley helps you to discover research relevant for your work.